CIBC Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-84,766
Closed -$1.1M 1463
2021
Q2
$1.1M Buy
84,766
+8,720
+11% +$111K ﹤0.01% 657
2021
Q1
$988K Buy
76,046
+1,838
+2% +$26.7K ﹤0.01% 667
2020
Q4
$1.02M Buy
74,208
+6,914
+10% +$101K ﹤0.01% 622
2020
Q3
$990K Buy
67,294
+3,214
+5% +$46.6K 0.01% 591
2020
Q2
$1.04M Buy
+64,080
New +$1.03M 0.01% 556

Other funds holding AUPH

CIBC Asset Management's AUPH Position: Q3 2021 in Review

CIBC Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2021, closing a stake of 84,766 shares — an estimated $1.1M sold.

CIBC Asset Management first reported a position in AUPH in Q2 2020 and held it in 5 quarters. The position peaked at $1.1M in Q2 2021. 166 funds tracked by Wall St. Rank hold AUPH as of Q3 2021.

  • CIBC Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • CIBC Asset Management sold 84,766 Aurinia Pharmaceuticals shares in Q3 2021, an estimated $1.1M.
  • CIBC Asset Management first reported a position in Aurinia Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • CIBC Asset Management's Aurinia Pharmaceuticals position peaked at $1.1M in Q2 2021.
  • 166 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2021.

Based on CIBC Asset Management's 13F filing for Q3 2021, filed 9 Nov 2021.